INS and Hypoglycemia: He was monitored by a continuous glucose monitoring system (CGM, Abbott Libre 2), and parameters of glycemic outcomes improved continuously; however, due to the accelerated weight loss on tirzepatide, avoiding hypoglycemia was challenging, with time below range (TbR) steadily increasing despite rapid and considerable reductions in insulin doses including discontinuation of prandial insulin (Fig. 2).